NCT03269682 (3D-III) is a clinical trial of 3D PD T1 MRI sequence in Ophthalmoplegia, sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

Who is sponsoring NCT03269682?

NCT03269682 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

What drugs are being tested in NCT03269682?

Interventions in NCT03269682: 3D PD T1 MRI sequence.

What condition does NCT03269682 study?

NCT03269682 studies Ophthalmoplegia.

Is NCT03269682 still recruiting?

NCT03269682 is currently completed. Last updated 17 September 2021.

Last reviewed 2021-09-17 · How we verify

NCT03269682: 3D-III

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence of Contrast Enhancement of the Oculomotor Nerve on 3D PD T1 MRI Sequence in Patients With Ophthalmoplegia

Completed Last updated 17 September 2021

What this trial tests

trial testing 3D PD T1 MRI sequence in Ophthalmoplegia in 134 participants. Completed in 16 April 2021.

Timeline

20 October 2017

Primary endpoint
16 April 2021

16 April 2021

Quick facts

Lead sponsor	Fondation Ophtalmologique Adolphe de Rothschild
Status	Completed
Study type	OBSERVATIONAL
Enrollment	134
Start date	20 October 2017
Primary completion	16 April 2021
Estimated completion	16 April 2021
Sites	1 location across France

Drugs / interventions tested

3D PD T1 MRI sequence

Conditions studied

Ophthalmoplegia — all drugs for Ophthalmoplegia →

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Ophthalmoplegia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oculomotor nerve (third cranial nerve or "III") palsy is a relatively frequent cause of consultation in ophthalmology. It may reveal a life-threatening pathology such as aneurysm rupture, pituitary apoplexy, and therefore need imaging in emergency. Apart from few extreme emergency situations, MRI of the oculomotor tract is the first-line examination required. In our usual clinical practice, we noticed in several patients unusual contrast enhancement within the oculomotor nerve on T1 sequence with gadolinium injection, observed in various locations along the nerve path (cavernous and/ or intra-orbital segment). This contrast enhancement, could confirm the nerve impairment This study aims to analyse the efficiency of a new sequence 3D PD T1 which isotropic spatial resolution less than 1mm, not yet described in the literature, to depict this enhancement. In patients with ophthalmoplegia involving probably the third cranial nerve, disclosing this MRI sign could help (i) to confirm the involvement of the oculomotor nerve and eliminate differential diagnoses such as myasthenia (ii) to orientate the etiological diagnosis (inflammatory or ischemic origin). This new sequence 3D PD T1 sequence focused on the III could thus be systematically included in the usual MRI protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03269682 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
Last refreshed: 17 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03269682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing